Literature DB >> 22626743

Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study.

Maurizio Landolina1, Giovanni B Perego, Maurizio Lunati, Antonio Curnis, Giuseppe Guenzati, Alessandro Vicentini, Gianfranco Parati, Gabriella Borghi, Paolo Zanaboni, Sergio Valsecchi, Maurizio Marzegalli.   

Abstract

BACKGROUND: Heart failure patients with implantable cardioverter-defibrillators (ICDs) or an ICD for resynchronization therapy often visit the hospital for unscheduled examinations, placing a great burden on healthcare providers. We hypothesized that Internet-based remote interrogation systems could reduce emergency healthcare visits. METHODS AND
RESULTS: This multicenter randomized trial involving 200 patients compared remote monitoring with standard patient management consisting of scheduled visits and patient response to audible ICD alerts. The primary end point was the rate of emergency department or urgent in-office visits for heart failure, arrhythmias, or ICD-related events. Over 16 months, such visits were 35% less frequent in the remote arm (75 versus 117; incidence density, 0.59 versus 0.93 events per year; P=0.005). A 21% difference was observed in the rates of total healthcare visits for heart failure, arrhythmias, or ICD-related events (4.40 versus 5.74 events per year; P<0.001). The time from an ICD alert condition to review of the data was reduced from 24.8 days in the standard arm to 1.4 days in the remote arm (P<0.001). The patients' clinical status, as measured by the Clinical Composite Score, was similar in the 2 groups, whereas a more favorable change in quality of life (Minnesota Living With Heart Failure Questionnaire) was observed from the baseline to the 16th month in the remote arm (P=0.026).
CONCLUSIONS: Remote monitoring reduces emergency department/urgent in-office visits and, in general, total healthcare use in patients with ICD or defibrillators for resynchronization therapy. Compared with standard follow-up through in-office visits and audible ICD alerts, remote monitoring results in increased efficiency for healthcare providers and improved quality of care for patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00873899.

Entities:  

Mesh:

Year:  2012        PMID: 22626743     DOI: 10.1161/CIRCULATIONAHA.111.088971

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  73 in total

1.  Impact of in-clinic follow-up visits in patients with implantable cardioverter defibrillators: demographic and socioeconomic analysis of the TARIFF study population.

Authors:  Renato P Ricci; Alfredo Vicentini; Antonio D'Onofrio; Antonio Sagone; Antonio Vincenti; Luigi Padeletti; Loredana Morichelli; Antonio Fusco; Filippo Vecchione; Francesco Lo Presti; Alessandra Denaro; Annalisa Pollastrelli; Massimo Santini
Journal:  J Interv Card Electrophysiol       Date:  2013-09-21       Impact factor: 1.900

2.  [Implantable cardioverter-defibrillator: Is remote monitoring obligatory?].

Authors:  Fritz W Horlbeck; J O Schwab
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-04-22

3.  REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study.

Authors:  Mateusz Tajstra; Adam Sokal; Arkadiusz Gwóźdź; Marcin Wilczek; Adam Gacek; Konrad Wojciechowski; Elżbieta Gadula-Gacek; Elżbieta Adamowicz-Czoch; Katarzyna Chłosta-Niepiekło; Krzysztof Milewski; Piotr Rozentryt; Zbigniew Kalarus; Mariusz Gąsior; Lech Poloński
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-12-25       Impact factor: 1.468

Review 4.  [Implantable cardioverter defibrillator].

Authors:  C Stellbrink; D Andresen; D Böcker; T Lewalter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-03

5.  Implantable cardioverter defibrillator remote monitoring is well accepted and easy to use during long-term follow-up.

Authors:  Loredana Morichelli; Antonio Porfili; Laura Quarta; Anna Sassi; Renato Pietro Ricci
Journal:  J Interv Card Electrophysiol       Date:  2014-09-26       Impact factor: 1.900

6.  Remote monitoring of implantable cardioverter-defibrillators. Problems and implications using a telemonitoring system.

Authors:  J Siebermair; S Clauss; E Martens; F Schuessler; N Oversohl; N Haserueck; H L Estner; S Kääb; R Wakili
Journal:  Herz       Date:  2014-05-23       Impact factor: 1.443

Review 7.  Trials of implantable monitoring devices in heart failure: which design is optimal?

Authors:  William T Abraham; Wendy G Stough; Ileana L Piña; Cecilia Linde; Jeffrey S Borer; Gaetano M De Ferrari; Roxana Mehran; Kenneth M Stein; Alphons Vincent; Jay S Yadav; Stefan D Anker; Faiez Zannad
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

8.  "We as Human Beings Get Farther and Farther Apart": the experiences of patients with remote monitoring systems.

Authors:  Abigale L Ottenberg; Keith M Swetz; Luke A Mueller; Samantha Gerhardson; Paul S Mueller
Journal:  Heart Lung       Date:  2013-04-10       Impact factor: 2.210

Review 9.  Implantable devices to monitor patients with heart failure.

Authors:  Nikolaos Karamichalakis; John Parissis; George Bakosis; Vasiliki Bistola; Ignatios Ikonomidis; Antonios Sideris; Gerasimos Filippatos
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 10.  The empirical foundations of telemedicine interventions for chronic disease management.

Authors:  Rashid L Bashshur; Gary W Shannon; Brian R Smith; Dale C Alverson; Nina Antoniotti; William G Barsan; Noura Bashshur; Edward M Brown; Molly J Coye; Charles R Doarn; Stewart Ferguson; Jim Grigsby; Elizabeth A Krupinski; Joseph C Kvedar; Jonathan Linkous; Ronald C Merrell; Thomas Nesbitt; Ronald Poropatich; Karen S Rheuban; Jay H Sanders; Andrew R Watson; Ronald S Weinstein; Peter Yellowlees
Journal:  Telemed J E Health       Date:  2014-06-26       Impact factor: 3.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.